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Abstract: Much evidence on the favorable effects of omega-3 ethyl esters on cardiovascular 
morbidity and mortality has been obtained in studies performed in healthy subjects and in different 
clinical settings. Here the clinical effects of omega-3 ethyl ester administration in patients with 
previous myocardial infarction or heart failure are reviewed, together with a discussion of underlying 
mechanisms of action. The pharmacokinetic and pharmacodynamic properties of omega-3 ethyl 
esters, as well as evidence concerning their safety and tolerability, are also reported.
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Introduction
Since the first evidence showing a protective effect against coronary artery disease 
(CAD), reported more than 30 years ago,1,2 several epidemiologic and clinical studies 
have indicated an inverse relationship between a diet rich in fish and cardiovascular 
(CV) morbidity and mortality.3–8 Two compounds of the omega-3 fatty acid class, 
namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), were presumed 
to be the active ingredients in fish.9 In the early 1980s, a large-scale method to purify 
EPA and DHA in the chemical form of an ethyl ester (EE) was developed for clinical 
use. Since then, several studies have investigated the role of isolated and combined 
EPA and DHA in the form of EE, especially with respect to CV disease prevention. 
Overall the results of these studies indicated a protective effect of omega-3 EE on 
total mortality and CV events.
In many European countries, oral omega-3 EE administration is indicated in 
adult patients for secondary prevention after myocardial infarction (MI) and for the 
  treatment of hypertriglyceridemia. In the US, omega-3 EE prescription is indicated 
for the treatment of triglyceride (TG) levels 500 mg/dL.
The purpose of this article is to review the pharmacologic properties of oral 
omega-3 EE, describing briefly the evidence for omega-3 EE and hypertriglyceridemia, 
and focusing attention on their efficacy and tolerability in secondary prevention after 
MI and in patients with heart failure (HF).
Triglycerides and cardiovascular risk
Evidence from observational and experimental studies suggests a relationship between 
triglycerides (TG) and CV disease.10–13 In the female population of the Framingham 
study, there was an increase in CV event rates as TG levels increased. In men the 
  correlation was not evident, although there was a 40% increase in incidence of coronary Journal of Multidisciplinary Healthcare 2010:3 80
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events as TG increased up to 200 mg/dL, without a further 
increase of risk at higher levels.10
Findings from the Münster Heart Study (PROCAM) 
showed that coronary event rates increased as TG levels 
increased from 200 mg/dL to 800 mg/dL, but decreased 
  significantly above this level.11 When TG levels were evaluated 
as a continuous variable, their level was not correlated with 
event rates. This finding likely reflects different atherogenicity 
of TG-rich lipoproteins at different TG levels; at the highest 
TG levels (800 mg/dL), less atherogenic chylomicrons 
predominate compared with the more atherogenic ones 
predominating in subjects with TG 800 mg/dL. Austin 
et al reported the existence of two low-density lipoprotein 
cholesterol (LDL-C) phenotypic distributions in relation to 
TG levels, ie, a less atherogenic phenotype A, characterized 
by large buoyant LDL particles that predominate with low 
TG levels, and a highly atherogenic phenotype B represented 
by small dense LDL particles that is prevalent with increased 
plasma levels of TG.14
The Baltimore Coronary Observational Long-Term Study 
was a long-term (20-year) study that evaluated predictors of 
coronary events in individuals who had documented CAD.13 
TG, as well as diabetes mellitus, were found to be important 
predictors, with a TG level 100 mg/dL increasing the risk 
for coronary events by 50% (95% confidence interval [CI]: 
1.1–2.1). After exclusion of diabetic patients, TG remained 
a significant predictor of new CAD events (relative risk [RR] 
1.8, 95% CI: 1.2–2.7).
The combined effect of baseline TG and lipoprotein 
 cholesterol levels on the incidence of CV endpoints 
was studied in the Helsinki Heart Trial. After five 
years of follow-up, the combination of LDL-C to high-
  density lipoprotein cholesterol (HDL-C) ratio 5 with 
TG 200 mg/dL revealed a subgroup of subjects at high CV 
risk (RR 3.8, 95% CI: 2.2–6.6).15 Some clinical studies, but 
not all, reported a reduction of the risk of CV events by treat-
ment with a fibric acid derivate in patients with high TG.
In patients with documented CAD, the Bezafibrate 
  Infarction Prevention trial (BIP) tested the effect of bezafibrate 
(400 mg/day) on a combined endpoint including death from 
CAD or nonfatal MI.16 The primary endpoint in BIP was not 
affected by fibrate therapy, although it induced a significant 
15.4% increase in HDL-C, and a significant 6.2% decrease in 
LDL-C. However, when data from the subset of patients with 
baseline TG 200 mg/dL were analyzed, a significant 40% 
reduction in the primary endpoint was observed.16
At variance with previous studies, the benefit reported in 
the Veterans Affairs High-Density Lipoprotein Intervention 
trial (VA-HIT) did not appear to be correlated with TG 
  reduction.17 In patients with CAD, there was an overall 22% 
reduction in the rates for fatal and nonfatal MI or death 
from CAD in subjects randomized to gemfibrozil. However, 
multiple regression analyses failed to find a consistent link 
between TG and CAD event rates for all levels of TG.17,18
More recently, a post hoc analysis of PROVE IT-TIMI 22, 
a study which compared the effects of standard versus 
intensive statin therapy on the incidence of CV events in 
patients hospitalized for an acute coronary syndrome (ACS), 
evaluated the relationship at 30 days between on-treatment 
TG levels, LDL-C, and a composite endpoint of death, MI, 
and recurrent ACS.12 On-treatment TG 150 mg/dL was 
independently associated with a lower risk of recurrent CHD 
events (adjusted hazards ratio [HR] 0.80, 95% CI: 0.66–0.97, 
P = 0.025). For each 10 mg/dL decrement in TG the risk of the 
composite endpoint was lowered by 1.6% (P  0.001) after 
adjustment for LDL-C. These results supported the concept 
that achieving low TG, beyond low LDL-C, may deserve 
additional consideration in patients after ACS.
Cardioprotective effects  
of omega-3 ethyl esters
Since the first evidence of a protective effect on CAD, many 
studies of fish intake or daily administration of fish oils 
have reported an inverse relationship with CV morbidity 
and mortality.3–8,19
In the early 1980s, EPA and DHA became available 
for clinical use in the purified chemical form of EE. Each 
1000 mg capsule of omega-3 EE contains approximately 
460 mg of EPA EE and 380 mg of DHA EE.20 Oral capsules 
of omega-3 EE, although providing fewer nutritional 
  elements than fish, have the advantage of avoiding the 
  possible negative effects of contaminants contained in fish 
(eg, dioxins, mercury, and polychlorinated biphenyls),21,22 the 
different action of various concentrations of EPA and DHA, 
and finally the effects of other fatty acids usually contained 
in fish oils. Since the commercialization of omega-3 EE, 
several studies have investigated isolated and combined 
preparations of EPA and DHA in the form of EE, especially 
with respect to CV prevention. Taken together, the results 
of the more recent studies confirmed that omega-3 fatty 
acids have cardioprotective effects,8,19,23–27 with an inverse 
  correlation between risk of CAD events and quantity of DHA 
in plasma and cellular phospholipids, which is closely linked 
to the DHA content of the myocardium.28
Oral omega-3 EE is able to improve the lipid profile 
  principally by reducing TG levels. However, in the Journal of Multidisciplinary Healthcare 2010:3 81
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major studies, changes in TC and HDL-C were generally 
not clinically significant, with a small net increase in 
LDL-C associated with a shift toward less atherogenic LDL 
subfractions.
In  patients  with  previous  MI,  the  addition  to 
  recommended treatment (eg, angiotensin-converting enzyme 
[ACE] inhibitors, antiplatelet agents, β-blockers, statins) of 
oral omega-3 EE 1000 mg/day was effective for secondary 
  prevention, reducing the risk of the composite endpoint of 
death + nonfatal MI + nonfatal stroke as well as various other 
endpoints (including death, CV death, and sudden death).23,29 
Post hoc results of analysis of individual events in the 
  composite endpoint, as well as the time-course assessment of 
benefit of omega-3 EE, suggest that the reduction in the risk 
of fatal events following omega-3 EE contribute importantly 
to the significant reductions observed in the risk of the 
  composite efficacy endpoints. The 45% reduction in the risk 
of sudden death was the major component in the reduction 
in risk of death shown in GISSI-Prevenzione.
The recent publication of the GISSI-HF trial results26 
confirmed previous less consistent evidence30–33 about a 
possible benefit of omega-3 EE in patients with HF. After 
a median follow-up of 3.9 years, 850–882 mg daily of 
EPA and DHA as EE induced a statistically significant risk 
  reduction in mortality and mortality + admission to hospital 
for a CV reason. Almost half of the absolute reduction of 
risk attributable to treatment was due to the reduction of 
ventricular arrhythmias, although the benefit in both mortality 
and hospitalization suggests that omega-3 EE might also 
positively affect the pathophysiologic mechanisms leading 
to the progression of HF.
Despite the results of many studies indicating cardiopro-
tective effects of omega-3 fatty acids, a Cochrane review34 
and a meta-analysis35 seem not to confirm these benefits. The 
Cochrane review,34 which included 89 studies (48 randomized 
controlled studies and 41 cohort studies), found that omega-
3 EE did not induce a significant reduction in the risk of 
total mortality (RR 0.87; 95% CI: 0.73–1.03) or combined 
CV events (RR 0.95; 95% CI: 0.82–1.12). The choice of 
inclusion of the DART (Diet and Reinfarction Trial) II in 
the analysis has generated considerable debate.27,36,37 After 
excluding DART II from the Cochrane analysis, the reduction 
of total death became statistically significant (RR 0.83; 95% 
CI: 0.75–0.91), but the risk of CV events did not change.34 
We updated the metanalysis of Leon et al38 including two 
recent clinical trials, GISSI-HF and OMEGA trial. We found 
that Omega-3 EE was associated with a 14% (OR 0.86; 
95% CI 0.79-0.94) significant risk reduction of death from 
cardiac cause and with barely not statistically significant risk 
reduction of all cause mortality (odds ratio [OR] 0.92; 95% 
CI: 0.83–1.03) (Figure 1), confirming findings reported by 
Leon et al.38 Of note, the beneficial effects on risk of CV 
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Figure 1 Randomized controlled trials reporting the effect of n-3 PUFA on cardiac death.
Abbreviations: CI, confidence interval; PUFA, polyunsaturated fatty acids.Journal of Multidisciplinary Healthcare 2010:3 82
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disease (CVD) appeared strong in the analysis of trials of 
secondary prevention, but not in those of the primary one.39 
This finding should be considered against the efficacy of 
omega-3 fatty acids in primary CVD prevention. In fact, 
only 50% of the causes of death are usually due to CVD in 
this clinical setting and are therefore potentially modifiable 
by omega-3 fatty acids. However, this finding, and the higher 
proportion of deaths due to CV causes in patients with CVD, 
translate into very different benefits on total mortality in 
patients with or without CVD.
Pharmacology
Pharmacokinetic properties
Oral administration of omega-3 EE to healthy volunteers40–42 
and hypertriglyceridemic subjects42 is followed by EPA 
and DHA absorption. After a first complete hydrolysis of 
omega-3 EE, EPA and DHA are absorbed and incorporated 
into plasma phospholipids and cholesterol esters, as reported 
in animal studies.20 Omega-3 EE oral administration in 
healthy volunteers for 12 weeks determined significant dose-
dependent increases in plasma phospholipid EPA and DHA 
  content.43 The same increases in plasma/serum phospholipid 
EPA and DHA content were seen in various patient 
  populations receiving oral omega-3 EE, such as those with 
combined hyperlipidemia,44 severe hypertriglyceridemia,45 
CAD,46 essential hypertension,47 and hypertensive heart 
transplant recipients.48
EPA and DHA concentrations in plasma phospholipids 
are related to the level of EPA and DHA incorporated into 
cell membranes.20 Omega-3 fatty acids are metabolized 
via three main pathways. Fatty acids are first transported 
to the liver for incorporation into lipoproteins, and then 
  channeled to peripheral lipid stores. Secondly, cell membrane 
 phospholipids are replaced by lipoprotein phospholipids, 
allowing EPA to act as a precursor for eicosanoids of the 
cyclo-oxygenase and lipoxygenase pathways.20,24,49 Finally, 
omega-3 fatty acids, like all other fatty acids, are oxidized to 
meet energy requirements.20,24 Uptake of EPA and DHA into 
serum phospholipids in recipients of omega-3 EE concentrate 
was independent of age (49 versus 49 years), and tended 
to be greater in women than in men.42
In healthy volunteers, the concomitant administration 
of omega-3 EE concentrate did not alter the steady-state 
  pharmacokinetics of atorvastatin (and its major active metab-
olites, 2-hydroxyatorvastatin and 4-hydroxyatorvastatin),50 
rosuvastatin,51 and simvastatin (and its major active metabo-
lite, β-hydroxysimvastatin).52 To support these findings, 
  experimental studies showed that undetectable concentrations 
(1 µmol/L) of the free forms of EPA and DHA are present 
in the circulation, so avoiding clinically significant inhibition 
of cytochrome P450 (CYP) enzymes.42
Pharmacodynamic properties
Although the mechanism of action of omega-3 fatty 
acids, including omega-3 EE, is not fully understood,40,42 
a number of effects of omega-3 EE that can positively 
interfere with the development or worsening of CV disease 
have been reported. Available evidence seems to suggest 
that EPA and DHA might differ in the mechanisms by 
which they exert their beneficial effect on the CV sys-
tem. This hypothesis needs to be carefully assessed and 
confirmed.53 In this review we discuss mechanisms which 
are likely to contribute to the benefit of omega-3 EE in 
post-MI and HF patients, including effects on lipid levels, 
  cardiac electrophysiology and hemodynamics, blood pres-
sure, endothelial function, thrombosis/homeostasis, and 
  atherogenesis and inflammation.
Lipid levels
Omega-3 EE improved the lipid profile in patients with 
mixed dyslipidemia,54 familial combined hyperlipidemia,55 
and hypertriglyceridemia.56–59 Significant reductions 
in TG, total cholesterol, non-HDL-C, very LDL-C 
(VLDL-C), VLDL-triglyceride and/or apoliprotein-B 
levels, and significant elevation in plasma or serum 
HDL-C and/or LDL-C levels with omega-3 EE 4000 mg/
day, alone56–59 or in combination with simvastatin 40 mg/
day54 were evident.
Similar data were reported in a review that demonstrated 
a dose-dependent reduction in TG levels in clinical studies.60 
In most studies, a 10%–33% reduction in TG levels was seen, 
that tended to be greater in studies of patients with higher 
TG levels at baseline. Total cholesterol and HDL-C did not 
significantly change, whilst a slight increase in LDL-C levels 
occurred.60
Omega-3 EEs exert a triglyceride-lowering effect 
through  two  main  mechanisms.40  Firstly  omega-3 
EE may reduce the hepatic synthesis of TG inhibiting acyl 
CoA:1,2-diacylglycerol acyltransferase,61 with reduced 
esterification and release of other fatty acids.20,61 Secondly, 
omega-3 EEs increase hepatic β-oxidation and upregulate 
fatty acid metabolism in the liver by stimulating peroxi-
some proliferator-activated receptor (PPAR) subtypes.62–64 
This in turn reduces the availability of free fatty acids for 
TG synthesis and reduces TG levels.20 Omega-3 EE also 
affects other nuclear receptors involved in the modulation Journal of Multidisciplinary Healthcare 2010:3 83
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of TG levels, so they may increase the removal of TG from 
  circulating VLDL via enzymatic upregulation.65
The elevation in LDL-C levels observed with omega-
3 EE seems to result from conversion of VLDL-C.66 In a 
study of 24 dyslipidemic obese patients, treatment with 
omega-3 EE 4000 mg/day significantly increased the mean 
  conversion rate of VLDL-apoliprotein B to intermediate 
  density lipoprotein (IDL)-apoliprotein B and LDL-apoliprotein 
B, as well as the mean conversion rate of IDL-apoliprotein 
B to LDL-apoliprotein B.67 Of note, the observed increase in 
LDL-C levels typically reflects a shift to larger, less atherogenic 
LDL particles.68 In patients with hypertriglyceridemia, despite 
the treatment with simvastatin 40 mg/day, those randomized 
to receive omega-3 EE 4000 mg/day for eight weeks showed 
a significantly greater median LDL particle size increase than 
patients on placebo. The direction of the shift in LDL particle 
size seemed to depend on the TG level; median changes in 
LDL particle size from baseline were +0.60, +0.40, +0.15, and 
-0.20 nm in patients with on-treatment TG levels of 149, 
149–192, 193–246, and 246 mg/dL, respectively. In the same 
  subgroups of patients, LDL subfraction pattern B (ie, smaller 
particles) was present in 68%, 79%, 93%, and 73% of patients 
at endpoint.69 Similar results were observed in a study54 con-
ducted in patients with mixed hyperlipidemia, ie, omega-3 EE 
4000 mg/day + simvastatin 20 mg/day induced a significant 
(P  0.05) increase from baseline in least-square mean LDL 
particle size compared with placebo + simvastatin 20 mg/day, 
with no between-group difference in LDL particle concentra-
tion. Significantly greater reductions from baseline in VLDL 
particle size and concentration were also observed between 
the two treatment groups. Both omega-3 EE 4000 mg/day 
and oral gemfibrozil 1200 mg/day improved the atherogenic 
LDL subfraction profile of patients with hypertriglyceridemia, 
elevating the cholesterol content of the more buoyant, less 
atherogenic LDL-1, LDL-2, and LDL-3 subfractions versus 
baseline. No significant differences in the LDL-4 and LDL-5 
subfractions versus baseline and no between-group differ-
ences in the cholesterol levels of the LDL subfractions were 
observed.59 In patients with familial combined hyperlipidemia, 
omega-3 EE treatment increased the LDL-C/apoliprotein-B 
ratio, indicating an elevation in the more buoyant and core-
enriched LDL-1 and LDL-2 subfractions, although the average 
LDL particle size was unchanged.55
Cardiac electrophysiology
Heart rate
According to the results of a meta-analysis,70 omega-3 
fatty acids (median dosage 3500 mg/day), significantly 
reduced heart rate by 1.6 beats per minute compared 
with placebo. Subgroup analysis showed this effect to be 
influenced by baseline heart rate; in patients with a mean 
heart rate 69 beats per minute at baseline there was a 
significant (P  0.001) reduction of 2.5 beats per minute, 
with no significant change in patients with a mean heart rate 
of 69 beats per minute at baseline.70
Arrhythmias
The antiarrhythmic effect is believed to be the main 
  mechanism explaining the reduced risk of sudden car-
diac death seen in patients with recent MI treated with 
omega-3 EE in the GISSI-Prevenzione study.23 This apparent 
  antiarrhythmic effect may result from a number of mecha-
nisms.
Experimental evidence suggests that n-3 polyunsatu-
rated fatty acids (PUFA) administered in the diet, added to 
culture media, or given intravenously, have direct effects on 
the trafficking of ion channels in cardiac membranes which 
may result in antiarrhythmic activity.71 The peculiarity of 
this action is that n-3 PUFA are likely to have a number 
of effects which could be pro- as well as antiarrhythmic. 
The sum of all these activities in modulating the electrical 
machinery of cardiac cells produces a positive “final” effect 
on life-threatening arrhythmias. The current hypothesis 
is that omega-3 EEs stabilize the electrical activity of 
myocytes by elevating the action potential threshold (ie, a 
stronger electrical stimulus is required to elicit an action 
potential), shortening the action potential duration, and 
prolonging the relative refractory time. The major contribu-
tors to the antiarrhythmic actions of omega-3 EE occur via 
inhibition of the voltage-dependent Na+ currents, which 
initiate the action potential in excitable tissue. The begin-
ning of the action potential may be also avoided, reducing 
delayed afterdepolarization through an inhibition of L-type 
Ca++ currents which prevent Ca++ overload. n-3 PUFA have 
also been reported to inhibit some potassium current com-
ponents, such as the two repolarizing K+ currents, the initial 
outward K+ (Ito) current, and the delayed rectifier K+ (IK) 
current, as well as the transient outward current responsible 
for the early repolarization phase. n-3 PUFA have been 
found to have an inhibitory effect on the cardiac Na+/Ca++ 
exchange (NCX) current. NCX protein expression in its 
forward mode (INCX ) provides a mechanism for extruding 
calcium from the cytosol and facilitates diastolic relaxation, 
and is often increased in patients with end-stage HF and 
with atrial fibrillation (AF).72 Decreased INCX may therefore 
result in a decreased propensity to develop delayed after Journal of Multidisciplinary Healthcare 2010:3 84
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depolarization and may contribute to the antiarrhythmic 
effects of n-3 PUFA.
The inhibition of intercellular communication may 
  represent an additional potential antiarrhythmic mechanism 
of n-3 PUFA. Treatment with n-3 PUFA reduced vulner-
ability to induction of AF in a dog model by reducing atrial 
expression of connexin.73
Furthermore, a cell membrane shift in the balance of n-3 
PUFA to n-6 PUFA might attenuate the production of n-6 
PUFA-derived eicosanoids, including thromboxane A2 and 
prostaglandins, which have been suggested to promote 
arrhythmias.74,75
Finally, omega-3 EEs may reduce arrhythmic events 
modulating autonomic tone.25,76 This hypothesis seems to 
be corroborated by some studies on heart rate variability 
(HRV), a risk marker for sudden cardiac death. Omega-3 fatty 
acids content of cell membranes was positively correlated 
with HRV ,77 and oral supplementation with 5200 mg/day of 
omega-3 fatty acids for three months in patients with recent 
MI significantly increased HRV.78 In patients with healed 
MI and left ventricular dysfunction, omega-3 fatty acids 
1500 mg/day significantly improved HRV in the high-fre-
quency band, compared with placebo, although there was 
no improvement in overall HRV.79 At variance with the 
previous evidence are the results of two studies showing that 
omega-3 EE at a daily dose of 1000 mg for three months in 
patients with mild hypertension80 and of 3000 mg for four 
months in post-MI patients,81 did not alter HRV indices to 
a significant extent.
Some recent studies in patients with an implantable car-
dioverter defibrillator (ICD) reported mixed results for an 
antiarrhythmic effect of omega-3 EE.82–84 Primary endpoints 
relating to the risk of ventricular arrhythmias ICD interven-
tion for ventricular fibrillation or ventricular tachycardia82–84 
or death82,83 were not improved by omega-3 EE to a significant 
extent. But when “probable” ventricular arrhythmic events 
were also considered, a significant 31% reduction in the 
primary endpoint was seen with omega-3 EE.83
It has been hypothesized that omega-3 fatty acids may 
have more favorable effects in certain subpopulations, in 
which the specific clinical setting and underlying arrhythmo-
genic mechanisms of initiation and propagation may be more 
susceptible to the antiarrhythmic effects of omega-3 EE. It 
should be noted, for example, that patients enrolled in ICD 
trials were different from those in GISSI-Prevenzione.23 The 
best evidence for the antiarrhythmic action of n-3 PUFA has 
been produced by experimental work performed in ischemia-
mediated animal models and in clinical trials carried out in 
post-MI patients in which ischemia-triggered arrhythmias 
may be predominant.
In addition, chronic oral dosing of omega-3 fatty acids, 
compared with acute or intravenous administration, may 
have different effects on cardiac electrophysiology, as 
suggested by experimental data showing that incorpora-
tion of n-3 PUFA into membrane phospholipids shortened 
the action potential without altering calcium transients 
and diastolic calcium levels in myocytes isolated from 
pigs.72 It has been hypothesized that tissue levels of n-3 
PUFA may influence the effects of oral administration of 
omega-3 EE; low basal tissue levels consequent to a daily 
intake 750 mg might amplify the antiarrhythmic effect 
of omega-3 EE supplements, with a first steep slope of 
the dose-response curve and a plateau thereafter, with no 
further beneficial effects on fatal arrhythmic events with 
higher doses.22 Such a hypothesis would explain the high 
protective effect of omega-3 EE against arrhythmic death 
in patients with low dietary intake of n-3 PUFA and HF26 
or ischemic heart disease.23,29
Cardiac hemodynamics
Cardiac function
Evidence suggests an improvement of cardiac output with 
omega-3 EE supplements by means of a positive action on 
systolic and diastolic function. Experimental evidence of a 
faster rate of cardiac muscle contraction and relaxation by 
n-3 PUFA with a consequent positive inotropic effect has 
been reported.85 In addition, EPA and DHA may prevent the 
myosin heavy chain isoform α to β switch, a marker of HF 
and left ventricular hypertrophy.86
Results of the Cardiovascular Health Study87 seem to 
confirm in older adults the findings previously shown in 
nonhuman primates88 of an association between fish intake 
and incremental stroke volume due to improvement of early 
and, possibly, late diastolic filling. Recently, chronic n-3 
PUFA administration in athletes has been reported to reduce 
heart rate and oxygen consumption during exercise without 
a decrement in performance, in part due to improved energy 
production and utilization by cardiac myocytes.89
Experimental data showed an increase in efficiency 
of oxygen use by the heart and skeletal muscles after n-3 
PUFA supplementation, possibly through improvement in 
  mitochondrial function and efficiency of ATP generation.90,91
EPA and DHA was shown to be able to modify 
  mitochondrial membrane properties, activate PPAR, and 
increase expression of metabolic enzymes, such as those 
involved in fatty acid oxidation and energy transduction, so Journal of Multidisciplinary Healthcare 2010:3 85
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preventing the increase in left ventricular end-diastolic and 
end-systolic volumes in a rat model of pressure overload.86
Blood pressure
According to the results of a meta-regression analysis, 
omega-3 fatty acid administration at a mean dosage of 
4100 mg/day was able to decrease mean blood pressure 
(BP) by 2.3/1.5 mmHg.92 Subgroup analyses demonstrated 
that BP was reduced to a greater extent in older (age 45 
years) versus younger participants and in hypertensive versus 
normotensive participants.
The findings of this meta-regression analysis were sup-
ported by studies in patients with essential hypertension,47,93 
hypertriglyceridemia,57 or combined hyperlipidemia,44,94 
patients who had undergone heart transplantation,95 or 
hypertensive heart transplant recipients,48 showing significant 
reductions in systolic and/or diastolic BP with omega-3 EE 
given at 2000–6000 mg/day. The reduction of BP may be 
due to effects on the arterial vascular bed. Improvement of 
endothelial dysfunction,96 reduction of systemic vascular 
resistance87 possibly by induction of nitric oxide production,97 
reduction of vasoconstrictive response to norepinephrine 
and angiotensin II,98 improvement of arterial wall compli-
ance,99 and enhancement of vasodilatory responses98 have 
been reported.
On the other side, some studies reported no evidence 
of effects of omega-3 EE on BP at doses of 1000 mg/day 
in post-MI patients,80 3000 mg/day in patients with mild 
hypertension,81 or 4000 mg/day of omega-3 EE in healthy 
volunteers.100
Endothelial function
A critical balance between endothelium-derived relaxing 
and contracting factors maintains vascular homeostasis and 
vascular smooth muscle tone. The endothelium, by releas-
ing nitric oxide (NO), promotes vasodilatation and inhibits 
inflammation, thrombosis, and vascular smooth muscle cell 
proliferation. In addition, NO opposes the actions of potent 
endothelium-derived contracting factors such as angioten-
sin-II and endothelin-1 (ET-1). Endothelial dysfunction 
is a pathologic state in which there is an imbalance in the 
relative contribution of endothelium-derived relaxing and 
contracting factors (such as ET-1, angiotensin, and oxidants). 
Endothelial dysfunction plays an important role in the clinical 
course of atherosclerosis. Common conditions predisposing 
to atherosclerosis, such as hypercholesterolemia, hyperten-
sion, diabetes, and smoking, are associated with endothelial 
dysfunction.
A small number of studies found endothelial function to 
be improved after fish oil ingestion by humans.8 In patients 
with hypercholesterolemia, baseline endothelium-dependent 
flow-mediated dilatation increased to a significantly greater 
extent with omega-3 EE 4000 mg/day than with placebo 
without affecting endothelium-independent dilation.101 In a 
six-week, randomized crossover trial, 20 children with famil-
ial (combined) hyperlipidemia received DHA 1200 mg/day. 
Endothelial function improved in this study, although levels 
of total cholesterol, LDL, and HDL increased, compared with 
subjects receiving the National Cholesterol Education Panel 
(NCEP)-II diet during the control period.102 In a random-
ized, double-blind study comparing 4000 mg/day EPA with 
4000 mg/day DHA and with 4000 mg/day olive oil (control) 
in 59 overweight, mildly hyperlipidemic men, DHA, but 
not EPA, improved the response to acetylcholine. DHA, 
however, improved the response to sodium nitroprusside and 
attenuated the constrictive response to norepinephrine, whilst 
olive oil had no effect.98 More recently, improvements in 
endothelial function have been reported in patients receiving 
omega-3 fatty acids.68 Thus the available evidence indicates 
that EPA-DHA improves endothelial function in patients with 
CV disorders. When EPA and DHA were compared, only 
DHA, but not EPA, was found to be effective.
Thrombosis and hemostasis
In vitro studies have shown that omega-3 fatty acids have 
inhibitory effects on thrombosis through reduction of platelet 
aggregation,103–105 and platelet thromboxane B2 response,105 
thus suggesting a potential cardioprotective effect through 
antithrombotic mechanisms.21 In healthy volunteers receiving 
omega-3 EE 1000–4000 mg/day, EPA was incorporated into 
platelets in a dose-dependent manner.43
Platelet-activating factor (an inducer of platelet aggre-
gation) was reduced by 900 mg/day EPA given for eight 
weeks in patients with type 2 diabetes mellitus, the effect 
being more pronounced after doubling the daily dose.106 In 
a six-week randomized, double-blind study, 4000 mg/day of 
EPA and 4000 mg/day DHA were compared with olive oil in 
59 hypertensive type 2 diabetics. DHA, but not EPA, reduced 
platelet response to collagen and associated thromboxane 
A2 formation, without differences in other parameters such 
as fibrinolytic activity.107 In patients with CAD, fibrinolytic 
activity, as assessed by plasminogen activator inhibitor-I 
activity levels, was found to be increased by 1800 mg/day of 
EPA,108 and by EPA–DHA 3400 mg/day.109 A three-month 
randomized study comparing 850 mg/EPA-DHA with usual 
care in 77 post-MI patients showed no differences in levels of Journal of Multidisciplinary Healthcare 2010:3 86
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fibrinogen or D-dimer, although von Willebrand factor was 
increased.110 Across clinical studies, omega-3 fatty acids did 
not show a consistent effect on hemostatic variables including 
levels of fibrinogen, factor VII or VIII or von Willebrand 
factor.60,111 Moreover, changes in levels of fibrinogen, factor 
VII or VIII, or von Willebrand factor generally did not 
  significantly differ between recipients of 1000–6000 mg/day 
omega-3 EE and controls in healthy volunteers,112 post-MI 
patients,110 patients with mild hypertension,81 patients with 
combined hyperlipidemia109 or patients undergoing coronary 
artery bypass graft (CABG) surgery.113
Bleeding time was prolonged in 40 post-MI patients 
after four weeks of 3400 mg/day EPA-DHA, without sig-
nificant alteration of other hemostatic parameters,114 and 
increased in one study in CAD patients.115 At variance with 
previous studies, omega-3 EE 6000 mg/day did not affect 
bleeding time at rest in patients with familial hypercholes-
terolemia,100,113 or in patients undergoing CABG surgery.113 
In addition, the incidence of bleeding episodes did not 
significantly differ between omega-3 EE 4000 mg/day and 
placebo recipients in a large study in patients undergoing 
CABG surgery who were also receiving warfarin or aspirin.116 
This finding is reassuring with regard to the current clinical 
relevance of the concern raised by older studies testing very 
high omega-3 fatty acid doses about a potential increased 
risk of bleeding due to the antithrombotic effect of omega-3 
fatty acids.21,117
However, hemocoagulatory tests should be performed to 
monitor adequately patients receiving anticoagulant therapy 
and the anticoagulant dosage adjusted as necessary.20
Atherogenesis and inflammation
Many effects of n-3 PUFA may positively interfere with 
atherosclerotic processes. Other than improvement in lipid 
levels, the effects on cell adhesion molecules, receptor 
scavenger expression, and vascular smooth muscle cell 
proliferation may reduce development of atherosclerotic 
lesions.118 Although treatment for six months with omega-3 
EE 6000 mg/day did not reduce the incidence of restenosis 
in patients who had undergone coronary angioplasty,119 
two meta-analyses suggested that omega-3 fatty acids may 
indeed prevent restenosis following this procedure.120,121 
In patients with planned carotid endarterectomy, admin-
istration of 2000 mg/day of omega-3 EE significantly 
increased plaque phospholipid EPA content compared 
with placebo.78 The potential improvement of plaque sta-
bility consequent to the increase of EPA and DHA122 was 
based on the finding that plaques from patients receiving 
omega-3 EE expressed significantly lower mRNA levels for 
matrix metalloproteinase (MMP)-7, MMP-9, MMP-12, and 
  intercellular adhesion molecule (ICAM)-1 than did plaque 
from placebo recipients.78 Omega-3 EE 4000 mg/day after 
six weeks’ therapy increased soluble E-selectin levels from 
baseline to a significantly greater extent than did placebo 
in patients with hypertriglyceridemia. However, after 
more than six months’ treatment, significant decreases in 
soluble E-selectin levels and in soluble ICAM-1 levels were 
observed.56 Gene expression of platelet-derived growth 
  factors A and B was downregulated in mononuclear cells 
from healthy volunteers who received omega-3 EE 7000 mg/
day for six weeks.123 Endotoxin-stimulated tumor necrosis 
factor-α production in peripheral blood mononuclear cells 
was significantly reduced from baseline in patients with 
severe HF who received omega-3 fatty acids 8000 mg/day 
for 18 weeks.124 It has been recently reported that the 
beneficial effects of n-3 fatty acid supplementation on 
  inflammatory processes may be due to an increase in EPA-
derived eicosanoids, PGE3 and LTB5, which are less active 
in the inflammatory response than AA-derived eicosanoids 
(PGE2 and LTB4).125
At variance with the above, some evidence did not report 
an improvement of inflammatory markers. C-reactive protein 
levels were not affected by treatment with omega-3 fatty 
acids.60,79 Compared with olive oil-treated controls, C-reactive 
protein, interleukin-6, and tumor necrosis factor-α were 
unaltered in 59 hypertensive Type 2 diabetics treated for six 
weeks with 4000 mg/ day of EPA or DHA.126 In post-MI 
patients treated with omega-3 EE 1000 mg/day, interleukin-6 
levels were not modified to a significant extent compared 
with controls.110 Finally, the effect of n-3 PUFA on oxidative 
stress remains controversial.118,126,127
Clinical efficacy
After myocardial infarction
GISSI-Prevenzione was a multicenter, randomized clinical 
trial that assessed the comparative efficacy of omega-3 EE, 
as monotherapy or in combination with tocopherol, ver-
sus tocopherol monotherapy or control (no treatment) as 
  secondary prevention for post-MI patients.23,128 From October 
1993 to September 1998, 11,323 patients who had suffered an 
MI within the previous three months (median 16 days) were 
randomized to receive omega-3 EE 1000 mg/day (n = 2835), 
omega-3 EE 1000 mg/day + tocopherol 300 mg/day 
(n = 2830), tocopherol 300 mg/day (n = 2830), or control 
(n = 2828) for 42 months. The patients’ mean age was 
59.4 years, with 16% aged 70 years, and 85.3% were male. Journal of Multidisciplinary Healthcare 2010:3 87
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At baseline, an ejection fraction of 30% and 0.31–0.40 was 
present in 2.6% and 11.1% of patients, respectively; 42.4% 
of patients were smokers, 35.6% were diagnosed with arterial 
hypertension, 4.4% had claudication, 14.8% had diabetes 
mellitus, 19.3% had ventricular arrhythmias, and 28.9% had 
a positive exercise stress test. Mediterranean dietary advices 
were given to all patients. Investigators were required to 
prescribe post-MI evidence-based therapy at baseline as well 
during the course of the study. At baseline, ACE inhibitors, 
antiplatelet agents, β-blockers, and lipid-lowering drugs 
were prescribed to 46.9%, 91.7%, 44.3%, and 4.7% of 
patients, respectively. The proportion of patients receiving 
the aforementioned medical treatments did not change much 
during the course of the study, but lipid-lowering treatments 
were prescribed to more than 30% of patients after six months 
and, at the end of the study, approximately 50% of patients 
was treated with statins.
The primary combined efficacy endpoints for the 
GISSI-Prevenzione study were the cumulative rate of 
all-cause death, nonfatal MI, and nonfatal stroke, and the 
cumulative rates of CV death, nonfatal MI, and nonfatal 
stroke. Secondary endpoints included the individual com-
ponents of the primary endpoints and the major causes 
of death.
The efficacy of the experimental treatments was 
  compared by two prespecified intention-to-treat analyses over   
42 months of follow-up. A four-way analysis of data compared 
the efficacy of omega-3 EE monotherapy, tocopherol mono-
therapy, and omega-3 EE + tocopherol with that of the control 
over the same time period; the efficacy of omega-3 EE + 
tocopherol was also compared with omega-3 EE monotherapy 
and tocopherol monotherapy. A two-way factorial analysis 
compared omega-3 EE-based therapy (omega-3 EE mono-
therapy and omega-3 EE + tocopherol groups) with that of 
non-omega-3 EE-based therapy (tocopherol monotherapy and 
control groups) and the efficacy of tocopherol-based therapy 
(tocopherol monotherapy and omega-3 EE + tocopherol 
groups) versus non-tocopherol-based therapy (omega-3 EE 
monotherapy and control).
The results of GISSI-Prevenzione showed that omega-3 
EE had a secondary preventive effect in patients with recent 
MI. The full efficacy profile of omega-3 EE is summarized 
in Table 1.
In the four-way analysis there were significant 
  reductions of both coprimary endpoints, ie, a 16% relative 
risk decrease for the combined endpoint of death, nonfatal 
MI, and nonfatal stroke (95% CI 3–27, P = 0.02) and a 
20% relative risk decrease for the secondary combined 
endpoint of CV death, nonfatal MI, and nonfatal stroke 
(95% CI 6–32, P = 0.006). Analyses of the individual 
components of the main endpoint were instrumental in 
speculation as to the mechanism of action of omega-3 EE. 
Almost all the benefit obtained with omega-3 EE in the 
combined endpoint was due to the decrease in fatal events 
(-21% of total deaths, -30% of CV deaths, and -44% of 
sudden deaths), suggesting that antiarrhythmic effect is the 
probable mechanism of action of omega-3 EE. With regard 
to nonfatal CV events, there was no significant difference 
between the treatment groups, and the results for the com-
bined treatment compared with controls on the primary 
combined endpoint and on total mortality were consistent 
with those obtained with omega-3 EE alone. No increased 
benefit was apparent when the rate of the combined endpoint 
of death, nonfatal MI and nonfatal stroke among patients 
receiving omega-3 EE + vitamin E was compared with that 
of the group receiving omega-3 EE alone or with that of 
patients treated with vitamin E alone. Patients receiving 
vitamin E and controls did not differ significantly when 
data were analyzed for the combined endpoint as well as 
for its individual components. Treatment with omega-3 EE 
alone significantly lowered the risk of total CHD events 
(0.78 [0.65–0.94], P = 0.008), whereas the reduction of risk 
observed with vitamin E was not statistically significant. No 
change in fatal + nonfatal stroke was found for any tested 
treatment. The results of the two-way analysis adjusted for 
interaction between the treatments were exactly the same 
as the results of the four-way analyses, with the interaction 
being statistically significant for CV, cardiac, and sudden 
death, and statistically relevant (P  0.10) for the second 
main endpoint and all CHD events (Table 1).
At six months, a significant reduction in TG levels was 
observed, but no clinically relevant change from baseline 
was shown for total cholesterol, LDL-C and HDL-C levels, 
fibrinogen, and glycemia.
A post hoc analysis of GISSI-Prevenzione29 assessed 
the time course of the benefit of omega-3 EE on mortality 
and supported the hypothesis of an antiarrhythmic effect 
of omega-3 EE. Survival curves for n-3 PUFA treatment 
diverged early after randomization, and total mortality was 
significantly lowered after only three months of treatment 
(RR 0.59; 95% CI 0.36–0.97; P = 0.037). The reduction in 
risk of sudden death was specifically relevant and statisti-
cally significant already at four months (RR 0.47; 95% 
CI 0.219–0.995; P = 0.048). A similarly significant, although 
delayed, pattern after six to eight months of treatment was 
observed for CV , cardiac, and coronary deaths.Journal of Multidisciplinary Healthcare 2010:3 88
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Another post hoc analysis31 of the GISSI-Prevenzione 
study reported that treatment with omega-3 EE was effective 
both in patients with and without left ventricular dysfunction 
(LVEF 50%) with an increase of benefit in those with left 
ventricular dysfunction, in whom omega-EE appeared more 
effective in reducing sudden death.
More recently, the randomized, double-blind, placebo-
controlled, multicenter OMEGA study evaluated the effect 
of omega-3 EE 1 g/day on the rate of sudden cardiac death in 
patients with MI in the previous 3–14 days, with a 12-month 
follow-up. Secondary endpoints included total mortality, 
reinfarction, revascularization, rhythm abnormalities in 
Holter monitoring, and stroke.129,130 A total of 3851 patients 
were included in the study, 74.4% were male and 25.6% 
female; 24.1% and 75.9% had a LVEF 0.45 and 0.45, 
respectively; 27.0% were diabetics and 1.8% had renal 
  failure. With regard to pharmacologic treatments at baseline, 
69.5% of patients were receiving an ACE inhibitor, 94% 
an antiplatelet agent, 85.7% a β-blocker, and 81.5% were 
receiving statins. Data were reported for per protocol popu-
lations. Preliminary data showed no significant difference 
in the incidence of sudden cardiac death between omega-3 
EE (1.5%) and placebo (1.5%) groups, neither with regard 
to the secondary endpoints, including total mortality (4.6% 
versus 3.7%), reinfarction (4.5% versus 4.1%), revasculariza-
tion (27.7% versus 29.1%), arrhythmic events (1.1% versus 
0.7%), and stroke (1.4 versus 0.7%). However the OMEGA 
study was designed assuming a sudden cardiac death rate 
of 1.9% in omega-3 EE recipients and 3.5% in placebo 
recipients, whilst the observed incidence was definitely 
lower (1.5% in both groups), thus making the trial heavily 
underpowered.130
Heart failure
Several observational and clinical studies have reported an 
association between fish consumption and reduced risk of 
HF.30,32,33,131 As already reported above, a post hoc analysis31 
of the GISSI-Prevenzione study23 indicated that treatment 
with 1 g/day of omega-3 EE had similar beneficial effects 
on total mortality in patients with (LVEF 50%, RR 0.76; 
0.60–0.96, P = 0.02) and without left ventricular dysfunction 
(LVEF 50%, RR 0.81; 0.59–1.10, P = 0.17). Moreover, 
the treatment appeared more effective in reducing sudden 
cardiac death in patients than those without left ventricular 
dysfunction.
Recently, the results of the GISSI-HF study, a random-
ized, placebo-controlled, multicenter trial investigating the 
efficacy of omega-3 EE in chronic HF were published.26   
A total of 6975 patients aged 18 years or older, with clinical 
evidence of HF of any cause and New York Heart Associa-
tion (NYHA) Class II–IV were randomized to 850–882 mg 
EPA-DHA daily as EE or matching placebo, and followed 
for a median of 3.9 years. Healthy lifestyle advice and 
  evidence-based medical therapy for HF were positively 
recommended to all participants. The mean age of the 
patients was 67 years (SD ± 11), 2947 (42%) were older than 
70 years, and 1516 (22%) were women. At baseline, 4425 
(63%), 2365 (34%), and 185 (3%) were in NYHA Class 
II, III, and IV, respectively; 653 (9%) had a LVEF 40%; 
987 (14%) were smokers, 3809 (55%) had hypertension, 
1974 (28%) diabetes mellitus, 610 (9%) peripheral vascular 
disease, and 256 (4%) neoplasia. With regard to medical 
history, 2909 (42%) had had an MI, 2137 (31%) a coronary 
revascularization, and 497 (4%) an ICD. Cause of HF was 
ischemic in 3467 (50%) patients, dilatative in 2025 (29%), 
hypertensive in 1036 (15%), and other or unknown in 447 
(6%). At study admission, recommended medical therapy 
for HF was widely used: 6520 (93%) patients were being 
treated with blockers of the renin-angiotensin system, 4522 
(65%) with β-blockers, 2740 (39%) with spironolactone, 
6260 (90%) with diuretics, and 4074 (58%) with antiplatelet 
agents.
Statistically  significant  risk  reductions  in  the 
two coprimary endpoints were observed in patients 
treated with omega-3 EE, ie, 9% and 8% for mortality 
and mortality + admission to hospital for a CV reason, 
respectively (Table 2). Main study results were consistent 
with those of the secondary analyses which were predefined 
in the study protocol, namely baseline characteristics, 
secondary outcomes, and per protocol analysis in the 4994 
who were compliant with experimental treatments (Table 2). 
Worsening of HF and presumed arrhythmic death accounted 
for 62% of all deaths and were lower in the omega-3 EE 
group than in the placebo group. Almost half of the absolute 
reduction of risk that was attributable to treatment was due 
to the reduction of ventricular arrhythmias (mortality, 0.9% 
of 1.8%; first CV hospitalization, 1.0% of 1.7%). Because of 
the high mortality and hospitalization rates in HF patients, 
the apparently modest relative risk reduction due to omega-3 
EE can be translated into an absolute benefit of 18 avoided 
deaths and 17 prevented CV hospitalizations for every 
1000 patients treated for 3.9 years with omega-3 EE. In 
addition, the benefit in both coprimary endpoints (mortality 
and hospitalization) suggests that omega-3 EE might also 
positively affect the pathophysiologic mechanisms leading 
to the progression of HF.Journal of Multidisciplinary Healthcare 2010:3 90
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Safety and tolerability
In general, omega-3 EE is safe and well tolerated. In hyper-
triglyceridemic patients receiving omega-3 EE, either alone 
or in combination with simvastatin, levels of hematocrit, 
hemoglobin, fasting blood glucose, HbA1c, creatinine, 
alanine transferase (ALT), aspartate transaminase (AST), 
creatine phosphokinase, fibrinogen, fructosamine, homocys-
teine, and uric acid were not altered to a clinically significant 
extent.45,46,132
However, in recipients of omega-3 EE + simvastatin 
40 mg/day, a mild clinically insignificant elevation in ALT, 
AST, and fasting glucose levels occurred more frequently 
than in placebo + simvastatin 40 mg/day recipients.132
With regard to safety and tolerability in post-MI 
patients, data from GISSI-Prevenzione23,133 are reported 
here (the results from OMEGA trial are not yet fully avail-
able). In 4.9% and 1.4% of patients receiving omega-3 
EE (1000 mg/day)-based therapy and in 2.9% and 0.4% 
of patients receiving tocopherol (300 mg/day)-based 
therapy, treatment-emergent gastrointestinal disturbances 
and nausea were observed. Cancer developed in 2.7% of 
patients receiving omega-3 EE alone, 2.3% of those receiv-
ing omega-3 EE + tocopherol, 2.6% of those receiving 
both, and 2.2% of control group; 1.5%, 0.9%, 1.2%, and 
1.2% of patients, respectively, developed nonfatal cancer. 
Therapy was discontinued by 11.6% of patients receiving 
omega-3 EE versus 7.3% of patients receiving tocopherol 
at 12 months while, at 42 months 28.5% versus 26.2% of 
patients discontinued therapy, respectively. Adverse events 
leading to permanent discontinuation of therapy occurred in 
3.8% of patients receiving omega-3 EE and 2.1% of patients 
receiving tocopherol.
Amongst the 6975 HF patients in the GISSI-HF trial, 
28.7% of those allocated to omega-3 EE and 29.6% of those 
receiving placebo were no longer taking the study drug for 
various reasons. An adverse drug reaction was the cause of 
permanent discontinuation in 2.9% of omega-3 EE recipients 
and 3.0% of placebo recipients, with gastrointestinal disor-
Table 2 GISSI-HF primary outcomes, secondary outcomes, and causes of death
n-3 PUFA  
(n = 3494)
Placebo  
(n = 3481)
Adjusted HR  
(95% CI)*
P value
Primary outcomes
  Deaths from any cause 955  
(27.3%)
1014  
(29.1%)
0.91 (0.833–0.998) 0.041
    Deaths from any cause or admitted  
in hospital for CV reasons
1981  
(56.7%)
2053  
(58.9%)
0.92 (0.849–0.999) 0.009
Secondary outcomes
  Deaths from a CV cause 712  
(20.4%)
765  
(22.0%)
0.90 (0.81–0.99) 0.045
  Patients who had a SCD 307  
(8.8%)
325  
(9.3%)
0.93 (0.79–1.08) 0.333
  Patient admissions: 1986 
(56.8%)
2028  
(58.3%)
0.94 (0.88–1.00) 0.049
    For a CV reason 1635  
(46.8%)
1687  
(48.5%)
0.93 (0.87–0.99) 0.026
    For HF 978  
(28.0%)
995  
(28.6%)
0.94 (0.86–1.02) 0.147
    Deaths from a CV cause or admitted  
for any reason
2157  
(61.7%)
2202  
(63.3%)
0.94 (0.89–0.99) 0.043
  Patients with fatal and nonfatal MI 107  
(3.1%)
129  
(3.7%)
0.82 (0.63–1.06) 0.121
  Patients with fatal and nonfatal stroke 122  
(3.5%)
103  
(3.0%)
1.16 (0.89–1.51) 0.271
Causes of death
  Acute MI 20  
(0.6%)
25  
(0.7%)
0.77 (0.43–1.39) 0.382
  Worsening HF 319  
(9.1%)
332  
(9.5%)
0.92 (0.79–1.07) 0.275
  Presumed arrhythmic 274  
(7.8%)
304  
(8.7%)
0.88 (0.75–1.04) 0.141
Notes: *95% CI was calculated with a Cox proportional hazards model with adjustment for admission to hospital for heart failure in the preceding year, previous pacemaker, 
and aortic stenosis. Data are number (%) unless otherwise stated.
Abbreviations: CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazards ratio; MI, myocardial infarction; PUFA, polyunsaturated fatty acids; SCD, sudden 
cardiac death.Journal of Multidisciplinary Healthcare 2010:3 91
Omega-3 ethyl esters in cardiovascular disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
ders being the most frequent cause in both groups (2.7% and 
2.6%, respectively).26
Available evidence indicates that oral administration of 
1000 mg omega-3 EE is generally well tolerated. Indeed, 
treatment-emergent adverse events associated with omega-3 
EE both in patients with hypertriglyceridemia and in more 
fragile populations, including patients with a previous MI 
or with HF, were generally gastrointestinal in nature and 
minor in intensity.
Conclusion
CVD results from the interaction of multiple risk factors. 
Therefore, the major cardiology societies provide a number 
of recommendations aimed at controlling these risk factors in 
their programs for CVD prevention.36,134 The first step in all 
programs for CVD prevention is lifestyle modification aimed 
at avoiding physical inactivity, an unhealthy diet, smoking, 
and overweight/obesity. The presence of a high level of risk 
or the failure of lifestyle modification warrants utilization 
of drug therapy.
The National Cholesterol Education Program Adult 
Treatment Panel III has identified elevated LDL-C levels 
as a major risk factor for CHD, and these are the primary 
target for lipid-lowering therapy. Elevated TG levels have 
also been identified recently as an independent risk factor 
for CHD.135 Oral omega-3 EE, alone or in combination with 
simvastatin or atorvastatin, was generally effective as an 
adjunct to diet in the treatment of hypertriglyceridemia in 
adult patients. Available evidence indicates that omega-3 
EE given at 3–4 grams per day significantly reduced TG 
levels, and significantly increased HDL-C levels compared 
with placebo.
The results of GISSI-Prevenzione demonstrated that oral 
administration of omega-3 EE 1000 mg/day was generally 
effective as an adjuvant therapy to standard treatment (eg, 
ACE inhibitors, antiplatelet agents, β-blockers, statins) for 
secondary prevention in post-MI adult patients. Indeed, 
omega-3 EE-based therapy significantly reduced the risk of 
the primary composite endpoint of death + nonfatal MI + 
nonfatal stroke (-16%) as well as various secondary end-
points (including death, CV death, and sudden death). The 
reduction in the risk of the coprimary composite efficacy 
endpoints, can be translated into an absolute benefit of four 
lives saved every 1000 post-MI patients treated with omega-3 
EE for one year (Figure 2). The observed reduction of fatal 
events, especially of sudden death (-2 events) contributed 
to the significant reductions in the risk of the coprimary 
composite efficacy endpoints.
The results of GISSI-HF showed that the administration of 
omega-3 EE (850–882 mg daily) in patients with chronic HF 
who were already receiving recommended medical therapy 
was effective in reducing the coprimary efficacy endpoints 
of all-cause mortality (-19%) and all-cause mortality or 
hospitalizations for CV reasons (-18%). These risk reduc-
tion can be translated into an absolute benefit of five lives 
saved every 1000 HF patients treated with omega-3 EE for 
one year (Figure 3). The treatment also avoided four hospital 
admissions for CV reasons. As in GISSI-Prevenzione,23 the 
main benefit appeared to be a reduction of arrhythmic events 
(-2 sudden deaths and -3 hospital admissions for ventricular 
arrhythmias, Figure 3).
The precise mechanisms of action of omega-3 EE are 
not yet fully understood. Findings from the GISSI studies 
DEATH
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−1
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−1
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−3
−4
−5
−6
HF sudden death other CV non CV
Figure 2 GISSI-Prevenzione study: Number of lives saved in every 1000 post-MI 
patients treated with omega-3 EE 1000 mg/day for one year.
Abbreviations: CV, cardiovascular; EE, ethyl esters; MI, myocardial infarction.
Figure 3 GISSI-HF study: Number of events avoided every 1000 HF patients treated 
with omega-3 EE 1000 mg/day for one year.
Abbreviations: CV, cardiovascular; EE, ethyl esters; MI, myocardial infarction.
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suggest that the major component of the observed benefit 
is an antiarrhythmic effect. This hypothesis appears to be 
supported by previous evidence from various sources, 
including epidemiologic studies examining fish consump-
tion and preclinical studies. Other factors that have been 
hypothesized to contribute to the cardioprotective effects of 
omega-3 fatty acids include effects on hemodynamics, lipid 
levels, endothelial function, thrombosis and hemostasis, 
atherogenesis, and inflammation.
According to the available evidence, the American Heart 
Association/American College of Cardiology, the European 
Society for Cardiology, and a number of national cardiac 
societies recommend the intake of 1 g/day of the two marine 
omega-3 fatty acids, EPA and DHA, for secondary preven-
tion, CV prevention, treatment post-MI, and prevention of 
sudden cardiac death.35,134,136–138
To date, in the various European countries, oral 
omega-3 EE (1000 mg/day) is indicated as a component 
of standard treatment for secondary prevention in post-MI 
patients, which includes ACE inhibitors, antiplatelet agents, 
β-blockers, and statins.20,42 It is also indicated for use alone 
(2000–4000 mg/day) or in combination with statins, as 
an adjunct to diet in the treatment of hypertriglyceride-
mia in adult patients who have not responded to dietary 
  measures.20,42 In the US, omega-3 EE is indicated as an 
adjunct to diet in the treatment of hypertriglyceridemia in 
adult patients.20,42
The recent results of GISSI-HF demonstrating a clinical 
benefit in patients with HF will probably be followed by 
the incorporation of omega-3 EE in the next guidelines for 
these patients. Indeed, despite available treatments which 
significantly decreased the per-year mortality in the “artificial 
scenario” of clinical trials, the risk of death in patients with 
HF remains too high in clinical practice.
Undoubtedly further studies are needed to determine the 
optimal dose as well as the effects of the various doses in dif-
ferent populations, and to clarify whether the more important 
mechanism for clinical benefit is the antiarrhythmic effect 
of omega-3 EE.
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